New combo therapy tested for Tough-to-Treat blood cancers
NCT ID NCT06743503
Summary
This early-stage study is testing the safety and initial effectiveness of an investigational cell therapy called UB-VV400, given alone and together with the drug rapamycin. It is for adults with aggressive B-cell lymphoma that has come back or not responded to other treatments, including some who have had prior CAR T-cell therapy. The main goals are to find the safest dose and see how patients' bodies handle the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGTianjin, China
Contact
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact
Conditions
Explore the condition pages connected to this study.